These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 20559263)
1. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]. Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Suppl 1):17-26. PubMed ID: 20559263 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]. Voznesenskaia TG; Fokina NM; Iakhno NN Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):17-26. PubMed ID: 21322821 [TBL] [Abstract][Full Text] [Related]
4. [Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]. Neznamov GG; Siuniakov SA; Teleshova SE; Chumakov DV; Reutova MA; Siuniakov TS; Mametova LE; Dorofeeva OA; Grishin SA Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):20-6. PubMed ID: 19491814 [TBL] [Abstract][Full Text] [Related]
5. [Prospects for using ladasten preparations in patients with irritable bowel syndrome]. Uspenskiĭ IuP; Fominykh IuA Eksp Klin Gastroenterol; 2010; (10):75-9. PubMed ID: 21434378 [TBL] [Abstract][Full Text] [Related]
6. [Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice]. Tallerova AV; Kovalenko LP; Durnev AD; Seredenin SB Eksp Klin Farmakol; 2011; 74(11):3-5. PubMed ID: 22288152 [TBL] [Abstract][Full Text] [Related]
7. [Asthenic post-COVID syndrome]. Khaibullina DK; Maksimov YN Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):61-69. PubMed ID: 36946399 [TBL] [Abstract][Full Text] [Related]
8. [Characteristics of ladasten effect in neurasthenia patients with various EEG parameters]. Neznamov GG; Bochkarev VK; Siuniakov SA; Grishin SA Eksp Klin Farmakol; 2008; 71(4):18-25. PubMed ID: 18819436 [TBL] [Abstract][Full Text] [Related]
9. Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome. Tallerova AV; Kovalenko LP; Durnev AD; Seredenin SB Bull Exp Biol Med; 2011 Nov; 152(1):58-60. PubMed ID: 22803040 [TBL] [Abstract][Full Text] [Related]
10. [An experience of using divasa in the treatment of cerebrovascular insufficiency]. Chukanova EI; Bogolepova AN; Chukanova AS Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):17-23. PubMed ID: 26356393 [TBL] [Abstract][Full Text] [Related]
11. [Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline)]. Nemkova SA; Semenov DV; Petrova EA; Savchenko DV; Zavadenko NN; Vozvyshaeva MY Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(7):27-34. PubMed ID: 31464286 [TBL] [Abstract][Full Text] [Related]
12. [Use of citrulline malate (stimol) in patients with autonomic dystonia associated with arterial hypotension]. Oknin VIu; Fedotova AV; Veĭn AM Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(1):30-3. PubMed ID: 11530455 [TBL] [Abstract][Full Text] [Related]
13. [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients]. Reutova MA; Siuniakov SA; Siuniakov TS; Dorofeeva OA; Mametova LÉ; Neznamov GG Eksp Klin Farmakol; 2011; 74(11):6-13. PubMed ID: 22288153 [TBL] [Abstract][Full Text] [Related]
14. [Asthenic disorders correction with Recognan]. Shavlovskaya OA; Bokova IA Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(3):57-62. PubMed ID: 38529864 [TBL] [Abstract][Full Text] [Related]
15. [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]. Neznamov GG; Bochkarev VK; Reutova MA; Shabanova AA; Siuniakov SA Eksp Klin Farmakol; 2012; 75(5):7-13. PubMed ID: 22834121 [TBL] [Abstract][Full Text] [Related]
16. [Effect of ladasten on the psychophysiological parameters of healthy volunteers]. Bogdan NG; Kolotilinskaia NV; Iarkova MA; Nadorov SA; Badyshtov BA; Seredenin SB Eksp Klin Farmakol; 2009; 72(3):3-9. PubMed ID: 19642584 [TBL] [Abstract][Full Text] [Related]
17. Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state. Tallerova AV; Kovalenko LP; Kuznetsova OS; Durnev AD; Seredenin SB Bull Exp Biol Med; 2014 Jan; 156(3):335-7. PubMed ID: 24771370 [TBL] [Abstract][Full Text] [Related]
18. [Nooklerin (deanoli aceglumas) in the treatment of astenic and cognitive disorders in patients with borderline psychopatological conditions]. Smulevich AB; Chitlova VV; Germanova KN Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):31-36. PubMed ID: 29053118 [TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and metabolic therapy of fatigue in the acute and early recovery periods of ischemic stroke]. Tynterova AM; Belousova YD; Reznik EY Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3. Vyp. 2):94-100. PubMed ID: 36950826 [TBL] [Abstract][Full Text] [Related]
20. [Prospects and possibilities for the treatment of patients with long COVID-19 syndrome]. Tanashyan MM; Raskurazhev AA; Kuznetsova PI; Bely PA; Zaslavskaya KI Ter Arkh; 2022 Dec; 94(11):1285-1293. PubMed ID: 37167167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]